Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol ER Open-Label Extension in Chronic Pain
NCT00487435Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of tapentadol in osteoarthritis (OA) and low back pain (LBP), sponsored by Johnson & Johnson. Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events at 52 weeks. Started Jun 2007; status: completed.
02
Drugs
tapentadol
03
Conditions
osteoarthritis (OA)low back pain (LBP)
Beyond the preview
Go deeper on NCT00487435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00487435.